Anna Garmpi1, Christos Damaskos2, Nikolaos Garmpis2, Alexandros Patsouras3, Spyridon Savvanis4, Nikolaos Gravvanis5, Evangelos Diamantis6. 1. Internal Medicine Department, Laiko General Hospital, Medical School, National and Kapodistrian University of Athens, Athens, Greece annagar@windowslive.com. 2. Second Department of Propedeutic Surgery, Laiko General Hospital, Medical School, National and Kapodistrian University of Athens, Athens, Greece. 3. Medical School, National and Kapodistrian University of Athens, Athens, Greece. 4. Department of Internal Medicine, Elpis General Hospital, Athens, Greece. 5. Health Center Peristeriou, Athens, Greece. 6. Department of Endocrinology and Diabetes Center, G. Gennimatas General Hospital, Athens, Greece.
Abstract
BACKGROUND/AIM: Streptococcus pneumoniae is the leading cause of bacterial pneumonia and an important cause of invasive disease. Despite the antiretroviral therapies, adults infected with human immunodeficiency virus (HIV) are at particular risk for invasive pneumococcal disease (IPD). The purpose of this study was to report the efficacy of the strategies currently being used in pneumococcal vaccination for HIV-infected adults. MATERIALS AND METHODS: A literature search was performed through electronic databases, for original articles in English, from years 2000 to 2019. Clinical trials controlled or randomized, and cohort studies were included. RESULTS: While 23-valent pneumococcal polysaccharide vaccine (PPV23) is recommended for immunocompromised patients, it has been reported that it is less suitable for HIV-infected patients. Recent guidelines have added pneumococcal conjugate vaccine (PCV) to the list of recommended vaccines. CONCLUSION: Further studies are needed to determine the optimal vaccines and intervals for subsequent revaccinations during the lifetime. Copyright
BACKGROUND/AIM: Streptococcus pneumoniae is the leading cause of bacterial pneumonia and an important cause of invasive disease. Despite the antiretroviral therapies, adults infected with human immunodeficiency virus (HIV) are at particular risk for invasive pneumococcal disease (IPD). The purpose of this study was to report the efficacy of the strategies currently being used in pneumococcal vaccination for HIV-infected adults. MATERIALS AND METHODS: A literature search was performed through electronic databases, for original articles in English, from years 2000 to 2019. Clinical trials controlled or randomized, and cohort studies were included. RESULTS: While 23-valent pneumococcal polysaccharide vaccine (PPV23) is recommended for immunocompromised patients, it has been reported that it is less suitable for HIV-infectedpatients. Recent guidelines have added pneumococcal conjugate vaccine (PCV) to the list of recommended vaccines. CONCLUSION: Further studies are needed to determine the optimal vaccines and intervals for subsequent revaccinations during the lifetime. Copyright
Authors: Daniel M Musher; Susan B Manof; Charlie Liss; Richard D McFetridge; Rocio D Marchese; Bonnie Bushnell; Frances Alvarez; Carla Painter; Michael D Blum; Jeffrey L Silber Journal: J Infect Dis Date: 2010-02-15 Impact factor: 5.226
Authors: Neil French; Stephen B Gordon; Thandie Mwalukomo; Sarah A White; Gershom Mwafulirwa; Herbert Longwe; Martin Mwaiponya; Eduard E Zijlstra; Malcolm E Molyneux; Charles F Gilks Journal: N Engl J Med Date: 2010-03-04 Impact factor: 91.245
Authors: D R Feikin; C M Elie; M B Goetz; J L Lennox; G M Carlone; S Romero-Steiner; P F Holder; W A O'Brien; C G Whitney; J C Butler; R F Breiman Journal: Vaccine Date: 2001-11-12 Impact factor: 3.641